Université de Montréal chemists looked at lab samples of patients who recovered from a mild case of COVID-19 and found that those over 50 produced more antibodies against the SARS-CoV-2 virus.
Currently available COVID vaccines require cold storage and sophisticated manufacturing capacity, which makes it difficult to produce and distribute them widely, especially in less developed countries.
Rutgers researchers studying COVID-19 have created a new way to deliver DNA molecules into skin cells, using a suction technique similar to the ancient healing practice of cupping.
Two new studies being presented at this year’s ACAAI Annual Scientific Meeting show most people who think they will have an allergic reaction, or who believe they have had an allergic response to the first vaccine, can safely be fully vaccinated.
Dos nuevos estudios que se presentan en la Reunión científica anual del ACAAI de este año muestran que la mayoría de las personas que piensan que tendrán una reacción alérgica, o que creen que han tenido una respuesta alérgica a la primera vacuna, pueden recibir todas las dosis de la vacuna de forma segura.
Covid passes and vaccine passports may promise the ideal solution to avoiding further lockdowns in the UK or pose a threat to people’s freedoms and right to privacy, experts argue in a debate published by The BMJ today.
Any decision to vaccinate all children under 12 years of age against COVID-19 must be done with due caution, considering in detail the risk and benefits, according to a new review by international paediatric vaccine experts.
Study suggests patient-related factors, healthcare providers, health systems and policy may facilitate access or barriers to vaccination
As part of a recently launched international phase 3 clinical trial, Montefiore Health System and Albert Einstein College of Medicine are investigating whether the Merck antiviral pill, molnupiravir, now approved in Britain for treating COVID-19, can prevent COVID-19 in unvaccinated individuals living with people who have contracted the disease. Montefiore-Einstein is the first and only New York State site for the trial and was selected due to its diverse patient population and expertise in clinical trials of COVID-19 and other infectious diseases.
Cedars-Sinai's COVID-19 vaccine drive-thru is now open to children 5 and older, following the U.S. Food and Drug Administration (FDA) authorization and Centers for Disease Control and Prevention (CDC) recommendation that the Pfizer-BioNTech vaccine is safe and effective in children.
The Centers for Disease Control and Prevention on Nov. 2 gave emergency authorization for use of the Pfizer BioNTech vaccine for children as young as 5 years old. A pediatrician answers questions.
CRI will bestow the 2021 William B. Coley Award for Distinguished Research in Basic Immunology on four mRNA vaccine scientists followed by roundtable on origin and future application to cancer treatment.
Rush psychologist offers help handling some tricky situations that may come up this holiday season
Joanna Drowos, D.O., M.P.H., M.B.A., FAU Schmidt College of Medicine, provides answers to some of the most frequently asked questions regarding the COVID-19 boosters and vaccines for children ages 5 to 11.
Simon Li, a principal investigator in the Rutgers pediatric clinical trial for the Pfizer-BioNTech COVID-19 vaccine, addresses parents’ questions
With two viruses threatening to make older adults sick this winter, a new poll shows most people over 50 have gotten protected by vaccines against both influenza and coronavirus, or plan to. And a majority of those who have gotten the COVID-19 vaccine plan to get an additional dose. But the poll also reveals major differences in vaccine attitudes between older adults, including those of different political leanings.
SEATTLE — Nov. 2, 2021 — Below are summaries of recent Fred Hutch research findings and other news.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that people with chronic inflammatory diseases, such as rheumatoid arthritis (RA), who take immunosuppressive therapy appear to have an impaired immunity response to SARS-CoV-2, the coronavirus that causes COVID-19, vaccines. Patients currently on glucocorticoids or B-cell depleting therapy appear to have an even more severely impeded vaccine response.
In a newly published study, researchers at the University of Maryland School of Medicine have detected antibodies primarily made in response to infections in the mucous membranes — in such areas as the lungs, intestines, or vagina — in study participants with malaria.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that in Alabama, one in 10 racial or ethnic minority patients with a rheumatic disease in a large rheumatology clinic said they were unlikely to get vaccinated against COVID-19.
The Morgridge Institute for Research will broadcast a free webinar on November 9, featuring a conversation with experts on the front lines of pediatric vaccine development and public health.
The University of Delaware's Aditya Kunjapur has been awarded the 2021 American Institute of Chemical Engineers (AIChE) Langer Prize for Innovation and Entrepreneurial Excellence, a highly competitive award that comes with a stipend to pursue “blue sky” ideas.
Researchers at Cedars-Sinai found that patients with inflammatory bowel disease (IBD)─whose treatment can weaken the immune system─produced a strong antibody response to COVID-19 vaccination. The study findings have been published in the Annals of Internal Medicine.
Following FDA authorization of the COVID-19 vaccine for 5- to 11-year-olds, Together by St. Jude releases a free coloring book that educates children on COVID-19 vaccines.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows patients using rituximab were able to produce antibodies against COVID-19 after receiving a third vaccine dose, even if there was no development of the antibody after the first two.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that nearly 30% of patients with lupus in a multi-ethnic and multi-racial study had a low response to the new COVID-19 vaccines.
New research presented this week at ACR Convergence, the American College of Rheumatology’s annual meeting, shows that the COVID-19 vaccine was not associated with severe disease flares in patients with rheumatic diseases.
In what is believed to be one of the largest studies of its kind, Johns Hopkins Medicine researchers have shown that antibody levels against SARS-CoV-2 (the COVID-19 virus) stay more durable — that is, remain higher over an extended period of time — in people who were infected by the virus and then received protection from two doses of messenger RNA (mRNA) vaccine compared with those who only got immunized.
NYU Langone rheumatologists are presenting their discoveries at the annual American College of Rheumatology conference, November 1 to November 9. The conference will be held virtually.
What if a few minutes of interaction with a chatbot could effectively address vaccine concerns?
As the Food and Drug Administration edges closer to emergency use approval of the Pfizer COVID-19 vaccine for children ages 5-11 – which could become available as soon as early November – Rutgers faculty and staff share reasons for why they'll vaccinate their children.
New UCLA research finds that misinformation and politicization, awareness of past injustices involving medical research, and fears about the inequitable distribution of vaccines all contributed to hesitancy to be vaccinated among Los Angeles' People of Color.
A year after launching one of the world’s largest COVID-19 antibody surveys, Texas CARES, public health experts at The University of Texas Health Science Center at Houston (UTHealth Houston) and the Texas Department of State Health Services (DSHS) are estimating that over 75% of Texans have COVID-19 antibodies.
The contributors are Kazan Federal University, Kazan State Medical Academy, Thapar Institute of Engineering and Technology, and the University of Liverpool.
The Delta variant of SARS-CoV-2 has swept the globe, becoming the dominant variant within just a few months.
New research addresses ongoing concerns regarding risks of allergic reactions after receiving mRNA COVID-19 vaccines, particularly for individuals with a history of severe allergic reactions.
Being vaccinated during childhood with the BCG (Bacille Calmette-Guérin) vaccine against tuberculosis is not a long-term protective factor against COVID-19, despite what was thought at the beginning of the pandemic.
Cleveland Clinic researchers have opened a novel study for a vaccine aimed at eventually preventing triple-negative breast cancer, the most aggressive and lethal form of the disease.
The Food and Drug Administration (FDA) is set to meet on October 26 to discuss the Emergency Use Authorization (EUA) of the Pfizer-BioNTech COVID-19 vaccine for children aged five to 11. Ahead of this meeting, Loyola Medicine is taking steps to ensure the health system is prepared to administer Pfizer vaccines to children if approval is granted.
A new analysis by a researcher at Beth Israel Deaconess Medical Center (BIDMC) finds a link between large gatherings of unvaccinated county residents – both students and non-students – and an increase in COVID-19 infections in the university’s community.
Lithium is a common medication prescribed to patients with psychiatric disorders, namely bipolar disorder, schizophrenia, and depression. It is used as a mood stabilizer and lessens the intensity of manic episodes, with particular benefit in reducing suicidality. While highly effective, the drug requires routine blood monitoring, which can be uncomfortable, expensive, and inconvenient for patients who must travel to clinical labs for frequent blood testing.
A booster dose of the mRNA-1273 COVID-19 vaccine given to rhesus macaques about six months after their primary vaccine series significantly increased levels of neutralizing antibodies against all known SARS-CoV-2 variants of concern, according to a new study from National Institutes of Health scientists and colleagues.
Using a novel technology, the lab of Michael Vahey at the McKelvey School of Engineering uncovered shape-shifting properties of a common respiratory virus.
Vaccination is over 90 per cent effective at preventing deaths from the Delta variant of Covid-19, according to the first country-level data on mortality.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
